Lupin Limited — Updates, 31-03-2025: Other Restructuring

Lupin Limited's Board has approved the transfer of its API R&D Division to wholly owned subsidiary Lupin Manufacturing Solutions Limited (LMSL) on a slump sale basis, with an expected consideration of ₹175-225 million. Additionally, the Board modified the earlier decision to transfer its Over-the-Counter Consumer Healthcare Business to incorporate one more brand into the new subsidiary, LupinLife Consumer Healthcare Limited (LCHL), with an anticipated consideration ranging from ₹8,000 million to ₹9,000 million. These strategic moves aim to streamline operations and enhance focus on core segments, likely paving the way for growth in the rapidly expanding OTC market while optimizing shareholder value. Investors may view this as a positive outlook for potential operational efficiencies and market positioning.